South Korea-based Samsung has revealed plans to commit W25 trillion to pursue new technology in areas including biopharmaceuticals and artificial intelligence.
France-based Sanofi has announced plans to launch a research and development hub in China to focus on digitalisation and big data analysis.
The Australian Competition and Consumer Commission said yesterday that it has sought to appeal against a decision by the Full Federal Court of Australia in a case involving Pfizer.
Humanitarian organisation Médecins Sans Frontières has challenged a patent owned by Gilead in China.
China-based pharmaceutical technology company WuXi AppTec has partnered with artificial intelligence specialist Insilico Medicine to integrate Insilico’s AI technology with WuXi’s laboratory infrastructure.
A court has rejected an appeal by the Australian Competition and Consumer Commission, in a decision which confirmed that deals made by Pfizer in relation to generic cholesterol-lowering medication do not constitute a misuse of its market power.
UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.
AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.
Biopharmaceutical company Celgene has ditched its trademark quarrel with the owners of India-based online pharmacies importing generics into the US.